Tailored drug dosing may shield kids with sickle cell from organ damage
NCT ID NCT07177300
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a personalized way to dose hydroxyurea for children with sickle cell anemia. Instead of using weight alone, doctors will measure how each child's body processes the drug to find the best dose. The goal is to see if this approach reduces damage to the brain, kidneys, heart, and spleen over time. The trial is recruiting 50 children aged 6 months and older.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- hydroxyurea
- What this could lead to
- If successful, this could improve how doctors prescribe hydroxyurea for sickle cell anemia, potentially reducing long-term organ damage in children.
- What could go wrong
- This is a small, early-phase study (50 participants) testing a dosing method, not a new drug. The approach may not prove better than standard weight-based dosing, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL ANEMIA (HBSS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cincinnati Children's Hospital Medical Center
RECRUITINGCincinnati, Ohio, 45229, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.